[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-364521-105":59,"doc-detail-364521-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","bispecific-antibodies-as-powerful-immunotherapeutic-agents-for-urological-cancers-recent-innovations-review","Bispecific antibodies as powerful immunotherapeutic agents for urological cancers - Recent innovations - Review","","Conventional immunotherapy remains a key cancer-treatment option, yet efficacy is constrained in urological cancers, notably prostate cancer, due to an immunosuppressive tumor microenvironment, limited drug delivery, abnormal immune responses, and collateral damage to normal cells. Bispecific antibodies (BsAbs), engineered proteins with two distinct antigen-binding domains, show promise across multiple tumor types. Key obstacles for BsAb use include tumor heterogeneity, immunogenicity, adverse effects, short serum half-life, low response rates, and drug resistance, which this review addresses by summarizing major BsAb platforms and approaches.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/bispecific-antibodies-as-powerful-immunotherapeutic-agents-for-urological-cancers-recent-innovations-review/364521/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/bispecific-antibodies-as-powerful-immunotherapeutic-agents-for-urological-cancers-recent-innovations-review/364521.png","ImageObject",300,407,{"name":92,"@type":93},"Noah","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is conventional immunotherapy less effective in urological cancers, especially prostate cancer?","Question",{"text":113,"@type":114},"Efficacy is limited by an immunosuppressive tumor microenvironment, difficulty in drug delivery, aberrant immune responses, and damage to normal cells.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What are bispecific antibodies (BsAbs) and how do they work?",{"text":118,"@type":114},"BsAbs are engineered proteins with two different antigen-binding domains that recognize distinct targets and redirect effector T cells and other immune cells to the tumor site.",{"name":120,"@type":111,"acceptedAnswer":121},"What challenges hinder broader clinical application of BsAbs?",{"text":122,"@type":114},"Key challenges include tumor heterogeneity, tumor microenvironment effects, immunogenicity, adverse effects, short serum half-life, low response rates, and drug resistance.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},364521,1790373275,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780","Ivyspring  \nInternational Publisher  \nInternationalJournal of Biological Sciences  \n2025; 21(4): 1410-1435. doi: 10.7150/ijbs.96155  \nReview  \nBispecific antibodies as powerful immunotherapeutic agents for urological cancers: Recent innovations based on preclinical and clinical evidence  \nKiavash Hushmandi1􀀍, Behzad Einollahi1􀀍, E Hui Clarissa Lee2,3, Reo Sakaizawa2,3, Antonino Glaviano4, Russel J. Reiter5, Seyed Hassan Saadat1, Marzieh Ramezani Farani6, Yun Suk Huh6, Amir Reza Aref7, Shokooh Salimimoghadam8, Alan Prem Kumar2,3,􀀍  \n1. Nephrology and Urology Research Center, Clinical Sciences Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.  \n2. Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.  \n3. NUS Center for Cancer Research (N2CR), Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.  \n4. Department of Biological, Chemical and Pharmaceutical Sciences and Technologies, University of Palermo, 90123 Palermo, Italy.  \n5. Department of Cell Systems and Anatomy, UT Health San Antonio, Long School of Medicine, San Antonio, Texas USA.  \n6. NanoBio High-Tech Materials Research Center, Department of Biological Sciences and Bioengineering, Inha University, 100 Inha-ro, Incheon 22212, Republic of Korea.  \n7. Department of Vitro Vision, DeepkinetiX Inc., Boston, MA, USA.  \n8. Department of Biochemistry and Molecular Biology, Faculty of Veterinary Medicine, Shahid Chamran University of Ahvaz, Ahvaz, Iran.  \n􀀍 Corresponding authors: Alan Prem Kumar ([apkumar@nus.edu.sg](apkumar@nus.edu.sg)); Kiavash Hushmandi ([houshmandi.kia7@ut.ac.ir](houshmandi.kia7@ut.ac.ir)); Behzad Einollahi ([Einollahib@bmsu.ac.ir](Einollahib@bmsu.ac.ir)).  \n© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)). See [https://ivyspring.com/terms](https://ivyspring.com/terms) for full terms and conditions.  \nReceived: 2024.03.10; Accepted: 2024.08.25; Published: 2025.01.27  \nAbstract  \nConventional immunotherapy has emerged as a key option for cancer treatment. However, its efficacy has been limited in urological cancers, especially prostate cancer, because of the immunosuppressive tumor microenvironment (TME), difficulty in drug delivery, aberrant immune response, and damage to normal cells. Bispecific antibodies (BsAbs) are engineered proteins with two different antigen-binding domains, designed using different technologies and in various formats. BsAb-based tumor immunotherapy has yielded optimistic results in preclinical and clinical investigations of many tumor types, including urological cancers. However, a series of challenges, including tumor heterogeneity, TME, Ab immunogenicity, adverse effects, serum half-life, low response rates, and drug resistance, hamper the application of BsAbs. In this review, we provide insights into the most common BsAb platforms with different mechanisms of action, which are under preclinical and clinical research, along with ways to overcome the challenges in BsAb administration for treating urological cancer.  \nKeywords: Urologic neoplasms; Bispecific antibodies; Immunotherapy; Drug delivery  \n1. Background  \nCommon urological cancers include prostate, kidney, bladder, testis, and penile cancers. While prostate, testicular, and penile cancers occur only in men, kidney and bladder cancers can affect both men and women, with men being more susceptible. Many novel therapeutic strategies have been introduced in recent years to manage cancer and increase the survival of patients; however, treating these cancer types, especially when they acquire a metastatic state, remains challenging, particularly in prostate carcinoma (1–3) .  \nIn recent decades, therapeutic antibodies (Abs) have been developed as important components of cancer treatment because of t","cbCaiauJfHQpgfJA","https://ap.wps.com/l/cbCaiauJfHQpgfJA","pdf",4133578,26,"English","# Abstract\n# Keywords\n# 1. Background\n## Common urological cancers and therapeutic challenges\n## Development of therapeutic antibodies and limitations\n## Role of bispecific antibodies in improving efficacy\n## Historical development of bispecific antibody concepts","[{\"question\":\"Why is conventional immunotherapy less effective in urological cancers, especially prostate cancer?\",\"answer\":\"Efficacy is limited by an immunosuppressive tumor microenvironment, difficulty in drug delivery, aberrant immune responses, and damage to normal cells.\"},{\"question\":\"What are bispecific antibodies (BsAbs) and how do they work?\",\"answer\":\"BsAbs are engineered proteins with two different antigen-binding domains that recognize distinct targets and redirect effector T cells and other immune cells to the tumor site.\"},{\"question\":\"What challenges hinder broader clinical application of BsAbs?\",\"answer\":\"Key challenges include tumor heterogeneity, tumor microenvironment effects, immunogenicity, adverse effects, short serum half-life, low response rates, and drug resistance.\"}]","Bispecific antibodies as powerful immunotherapeutic agents for urological cancers - Recent innovations - Review | PDF",1790157935,66,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8e260731247bd602a51ffb8ba1a4d7ea.webp",983,1272,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/98cccc7d27c8849b7f9aa7dd799f9edb.webp",982,1270,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/32eb8c79829175471afa0e8412e35cd4.webp",981,1269,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/51901e2317a696e2c8c08ba5d0f50466.webp",980,1268]